BIO’s John Crowley on RFK Jr. and tariffs

April 11, 2025

Sponsored By

Is there more funding coming for the biotech industry? Will the pharmaceutical industry be hit with tariffs? And is it possible to reason with RFK Jr.?

We talk about all that and more on this week's episode of "The Readout LOUD," STAT's biotech podcast. John Crowley, the CEO of industry lobbying group BIO, joins us to discuss the layoffs at the Food and Drug Administration, RFK Jr.'s comments on Novavax's Covid-19 vaccine, and how the trade group is communicating with the Trump administration.

Then, Adam, Elaine, and Allison discuss the latest news on the stock market and a congressional advisory group's recommendation that $15 billion be invested in U.S. biotechnology to ward off encroaching competition from China.

Listen Now

You can learn more about the congressional report here; for a running list of which top FDA officials are no longer with the agency, go here; to read Crowley's First Opinion article on changes at the FDA, go here; and to read Adam's latest thoughts on the tariffs and the biotech doom loop, go here.